The collaboration between Aptar Digital Health and Chiesi will provide patients with a comprehensive set of services and solutions
With the goal of bringing a disease mangement platform for asthma and chronic pulmonary disease (COPD) to market, Aptar Digital Health, a division of Aptar Pharma, an international leader in drug delivery and active material science solutions and services, has formed a strategic partnership with the Chiesi Group, an international biopharmaceutical and healthcare group with a focus on research.
This partnership brings a brand-new Disease Management Platform, recently announced by Aptar, that will enable patients to better understand and control their diseases. The data-driven insights will assist healthcare professionals in better managing patients and establishing evidence for emerging reimbursement arrangements in the field of asthma and COPD digital health.
This platform combines both the pharmacological and behavioral aspects of respiratory disease management with a comprehensive set of services and solutions.
It also provides adherence monitoring, lung function assessments, symptoms reporting, and disease triggers identification, and also enables communication with health coaches and care teams. The initial focus will be on Europe, with the potential for future expansion into other regions.
Healthcare systems in Europe are burdened with respiratory illnesses like asthma and COPD. Over 60 million people age 30 to 79 suffer from COPD, which is estimated to affect 6% of the European population. COPD and asthma are the biggest economic burdens on European health services, amounting to around €40 billion each year.
Aptar Digital Health, with its technology and pharma expertise, is uniquely positioned to offer such a complete solution – from software to connected devices to patient monitoring and data analysis,” said Gael Touya, President of Aptar Pharma. “We are delighted to partner with Chiesi and excited to be able to actively contribute to expanding patient access to holistic, end-to-end services that will durably enhance their respiratory disease management.
This collaboration reflects our commitment to providing best-in-class level of care for people living with COPD and asthma, going beyond treatments alone and focusing on the patient experience,” commented Alessandro Chiesi, Chief Commercial Officer of the Chiesi Group. “We are looking forward to leveraging Aptar Digital Health’s deep expertise in disease management, with the goal to improve the quality of life of patients afflicted with respiratory diseases and procure tools that contribute to the sustainability of healthcare services for chronic conditions.
Added Sai Shankar, President, Aptar Digital Health, “This collaboration leads the way for our recently launched Disease Management Platform offering and reinforces our conviction that end-to-end solutions designed to improve patient care are the future of healthcare“.
Download full Press Release.
Reference Sources:
ec.europa.eu
www.england.nhs.uk
www.erswhitebook.org
The cost of respiratory disease – ERS (erswhitebook.org)
